• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Fresenius Medical Care Listed in The Dow Jones Sustainability World Index and for the 15th Time in The Dow Jones Sustainability Europe Index

    12/23/24 9:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care
    Get the next $FMS alert in real time by email
    • Ranking puts Fresenius Medical Care among the best-in-class sustainability performers in the world and Europe
    • The company recorded progress towards its sustainability targets
    • Sustainability is one of the essential drivers for future

    BAD HOMBURG, Germany, Dec. 23, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has been recognized as a sustainability leader with the inclusion in the Dow Jones Sustainability World Index and with the inclusion in the Dow Jones Sustainability Europe Index for the 15th time. Dow Jones Sustainability Index (DJSI) is one of the world's leading ESG (Environmental, Social, Governance) stock indices.

    Fresenius Medical Care Listed in The Dow Jones Sustainability World Index and for the 15th Time in The Dow Jones Sustainability Europe Index

    Helen Giza, CEO of Fresenius Medical Care AG, said: "We believe that sustainability and excellent patient care are inextricably linked. I am very proud that our employees' commitment to our sustainability efforts has been recognized through the inclusion in the indices. Considering sustainability in our products and the way we work helps to ensure that we provide excellent, high-quality services for future generations."

    Fresenius Medical Care continuously incorporates sustainability into its global business operations. The company's approach centers on three strategic focus areas:

    • Enhancing quality of care and access to healthcare,
    • building the best teams to serve patients, and
    • reducing the company's environmental footprint.

    In 2023, FME has reported progress toward its sustainability targets and governance:

    • Fresenius Medical Care improved its Net Promoter Score to 72, reflecting a high patient satisfaction with its services.
    • The company increased the share of women in the top two management levels below Management Board to 34%, underlining its commitment to diversity, equity and inclusion.
    • FME moved ahead with its climate neutrality action plan, with Scope 1 and 2 emissions in 2023 decreasing by 16% from a 2020 baseline. The reduction of CO2e emissions is included in the targets for the long-term compensation of the Management Board members for 2024.
    • In 2024 the company signed five virtual power purchase agreements for approximately 580 gigawatt hours per year with wind and solar farms in Germany and the U.S. It also submitted the commitment letter to the Science Based Target initiative (SBTi).

    The Dow Jones Sustainability Indices are the longest-running global sustainability benchmarks. Each year, over 13,000 companies are invited to participate in the Corporate Sustainability Assessment (CSA). Approximately 3,500 of the largest companies worldwide are eligible for inclusion in any DJSI. The annual review evaluates companies' sustainability performance in areas relevant to each industry.

    An overview of Fresenius Medical Care's progress in sustainability can be found in the company's non-financial group report here.

    About Fresenius Medical Care:

    Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.1 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,732 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 308,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

    For more information visit the company's website at www.freseniusmedicalcare.com.

    Disclaimer:

    This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.

    Media contact

    Christine Peters

    T +49 160 60 66 770

    [email protected]

    Contact for analysts and investors

    Dr. Dominik Heger

    T +49 6172 609 2601

    [email protected]

    www.freseniusmedicalcare.com

    Fresenius Medical Care starts the year with strong earnings growth (PRNewsfoto/Fresenius Medical Care North Am)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-listed-in-the-dow-jones-sustainability-world-index-and-for-the-15th-time-in-the-dow-jones-sustainability-europe-index-302338375.html

    SOURCE Fresenius Medical Care Holdings, Inc.

    Get the next $FMS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FMS

    DatePrice TargetRatingAnalyst
    12/2/2024Underperform → Neutral
    BofA Securities
    11/6/2024$25.60Buy
    Berenberg
    1/8/2024Equal-Weight → Underweight
    Morgan Stanley
    11/24/2023Reduce → Hold
    HSBC Securities
    11/17/2023Hold → Buy
    Societe Generale
    8/14/2023Buy → Neutral
    UBS
    8/1/2023Neutral
    Citigroup
    7/12/2023Buy
    Goldman
    More analyst ratings

    $FMS
    SEC Filings

    See more
    • SEC Form 6-K filed by Fresenius Medical Care AG

      6-K - Fresenius Medical Care AG (0001333141) (Filer)

      5/6/25 4:12:11 PM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 6-K filed by Fresenius Medical Care AG

      6-K - Fresenius Medical Care AG (0001333141) (Filer)

      5/6/25 6:01:20 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 6-K filed by Fresenius Medical Care AG

      6-K - Fresenius Medical Care AG (0001333141) (Filer)

      4/10/25 6:01:34 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care

    $FMS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fresenius Medical Care starts 2025 with strong organic revenue and income growth

      Strong organic revenue growth1 of 5% driven by Care Enablement and Care DeliveryStable U.S. same market treatment development despite impact from a severe flu seasonFME25 savings of EUR 68 million contributed to earningsOperating income2 grew 11% at constant currency resulting in margin expansionReported operating income grew by 35% and reported net income3 by 113%Net leverage ratio further improved to 2.8x and FY 2025 outlook confirmedBAD HOMBURG, Germany, May 6, 2025 /PRNewswire/ -- "The results of the first quarter of 2025 once again demonstrate our continuous operational and financial progress as we are executing the third and last year of our current strategic plan," said Helen Giza, Ch

      5/6/25 7:00:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Fresenius Medical Care publishes its joint Annual Report and Sustainability Statement for 2024: Building the Momentum

      In 2024, the operating model to deliver the highest quality of patient care was further optimized by enhancing financial returns, and creating value for shareholdersFresenius Medical Care delivered 18% operating income growth on an outlook base in 2024Ongoing progress has been achieved in key areas of sustainability: notably in patient care and environmental footprintBAD HOMBURG, Germany, March 13, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, released its 2024 Annual Report including its Sustainability Statement. By "Building the Momentum", the Annual Report highlights financial, social, and ecol

      3/13/25 8:00:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Fresenius Medical Care delivers 18% earnings growth in 2024 and continues the acceleration momentum into 2025

      Organic revenue growth1 of 4% driven by Care Enablement and Care DeliveryUnderlying U.S. same market treatment growth further accelerated in Q4 and turned positive for the full yearAccumulated savings of the FME25 program already reached EUR 567 million and 2025 target raised to EUR 750 millionWith 18% operating income2 growth top end of the 2024 outlook range reachedReported operating income grew by 2%, reported net income3 by +8%Net financial leverage ratio reduced from 3.2x to 2.9x and dividend is planned to be raised by 21%High teens to high twenties percent earnings growth in 2025, translating into an 11 to 12% marginBAD HOMBURG, Germany, Feb. 25, 2025 /PRNewswire/ -- "Fresenius Medical

      2/25/25 7:00:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care

    $FMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Fresenius Medical Care AG

      SC 13G - Fresenius Medical Care AG (0001333141) (Subject)

      11/14/24 4:08:53 PM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G/A filed by Fresenius Medical Care AG (Amendment)

      SC 13G/A - Fresenius Medical Care AG (0001333141) (Subject)

      2/13/24 1:36:58 PM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13D/A filed by Fresenius Medical Care AG (Amendment)

      SC 13D/A - Fresenius Medical Care AG (0001333141) (Subject)

      12/7/23 11:45:52 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care

    $FMS
    Leadership Updates

    Live Leadership Updates

    See more
    • Fresenius Medical Care appoints Jörg Häring as new Management Board member responsible for Legal, Compliance and Human Resources

      Effective June 1, the Legal, Compliance, and Human Resources functions will be combined in a new Management Board roleJörg Häring contributes his extensive expertise from the energy, industry, and healthcare sectorsBAD HOMBURG, Germany, March 13, 2024 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has announced today the appointment of Jörg Häring (54) as its new Global Head of Legal, Compliance and Human Resources. Häring, who will join the company as a member of the Management Board, will start on June 1, 2024, and also assume the role of Labor Director.

      3/13/24 10:00:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Fresenius Medical Care AG nominates Six Employee Representatives to the Supervisory Board

      BAD HOMBURG, Germany, Feb. 5, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has nominated six employee representatives as members of the company's Supervisory Board. Effective January 26, the competent court approved the company's application for the judicial appointment of the six employee representatives. The judicial appointment will remain effective until completion of the election of employee representatives by the FME workforce located in Germany.   Fresenius Medical Care succ

      2/5/24 8:57:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Fresenius Medical Care simplifies corporate structure by converting into a German stock corporation

      Extraordinary General Meeting approves conversion of Fresenius Medical Care's legal formSeveral advantages including faster and more agile decision-makingMichael Sen elected as Chair of new Supervisory BoardConversion expected to be completed by the end of 2023WALTHAM, Mass., July 14, 2023 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, held an Extraordinary General Meeting (EGM) today. The Company's shareholders approved all agenda items with large majority, including the conversion of Fresenius Medical Care from the legal form of a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA) into a

      7/14/23 11:34:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care

    $FMS
    Financials

    Live finance-specific insights

    See more
    • Fresenius Medical Care starts 2025 with strong organic revenue and income growth

      Strong organic revenue growth1 of 5% driven by Care Enablement and Care DeliveryStable U.S. same market treatment development despite impact from a severe flu seasonFME25 savings of EUR 68 million contributed to earningsOperating income2 grew 11% at constant currency resulting in margin expansionReported operating income grew by 35% and reported net income3 by 113%Net leverage ratio further improved to 2.8x and FY 2025 outlook confirmedBAD HOMBURG, Germany, May 6, 2025 /PRNewswire/ -- "The results of the first quarter of 2025 once again demonstrate our continuous operational and financial progress as we are executing the third and last year of our current strategic plan," said Helen Giza, Ch

      5/6/25 7:00:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Fresenius Medical Care publishes its joint Annual Report and Sustainability Statement for 2024: Building the Momentum

      In 2024, the operating model to deliver the highest quality of patient care was further optimized by enhancing financial returns, and creating value for shareholdersFresenius Medical Care delivered 18% operating income growth on an outlook base in 2024Ongoing progress has been achieved in key areas of sustainability: notably in patient care and environmental footprintBAD HOMBURG, Germany, March 13, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, released its 2024 Annual Report including its Sustainability Statement. By "Building the Momentum", the Annual Report highlights financial, social, and ecol

      3/13/25 8:00:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Fresenius Medical Care delivers 18% earnings growth in 2024 and continues the acceleration momentum into 2025

      Organic revenue growth1 of 4% driven by Care Enablement and Care DeliveryUnderlying U.S. same market treatment growth further accelerated in Q4 and turned positive for the full yearAccumulated savings of the FME25 program already reached EUR 567 million and 2025 target raised to EUR 750 millionWith 18% operating income2 growth top end of the 2024 outlook range reachedReported operating income grew by 2%, reported net income3 by +8%Net financial leverage ratio reduced from 3.2x to 2.9x and dividend is planned to be raised by 21%High teens to high twenties percent earnings growth in 2025, translating into an 11 to 12% marginBAD HOMBURG, Germany, Feb. 25, 2025 /PRNewswire/ -- "Fresenius Medical

      2/25/25 7:00:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care

    $FMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Fresenius Medical upgraded by BofA Securities

      BofA Securities upgraded Fresenius Medical from Underperform to Neutral

      12/2/24 8:51:34 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Berenberg initiated coverage on Fresenius Medical with a new price target

      Berenberg initiated coverage of Fresenius Medical with a rating of Buy and set a new price target of $25.60

      11/6/24 6:26:23 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Fresenius Medical downgraded by Morgan Stanley

      Morgan Stanley downgraded Fresenius Medical from Equal-Weight to Underweight

      1/8/24 7:47:44 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care